• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    ProMIS Neurosciences Inc. - Common Shares (NQ: PMN )

    1.212 +0.012 (+0.98%)
    Streaming Delayed Price Updated: 3:58 PM EDT, Aug 14, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 32,338
    Open 1.299
    Bid (Size) 1.200 (6)
    Ask (Size) 1.300 (41)
    Prev. Close 1.200
    Today's Range 1.190 - 1.299
    52wk Range 0.9500 - 3.100
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
    It's time to dive into the biggest pre-market stock movers for Monday morning with all of the latest news affecting shares today! 
    Via InvestorPlace
    Why Ainos Shares Are Trading Higher By Around 38%; Here Are 20 Stocks Moving Premarket
    Via Benzinga

    Performance

    YTD
    -12.80%
    -12.80%
    1 Month
    -44.90%
    -44.90%
    3 Month
    -37.54%
    -37.54%
    6 Month
    -40.89%
    -40.89%
    1 Year
    -49.51%
    -49.51%

    More News

    Read More
    PMN Stock Earnings: ProMIS Neurosciences Beats EPS for Q2 2024
    Via InvestorPlace
    ProMIS Neurosciences Announces Second Quarter 2024 Financial Results and Recent Highlights
    From ProMIS Neurosciences Inc.
    Via GlobeNewswire
    ProMIS Neurosciences Announces Data on the Pathogenic Role of Toxic Misfolded SOD1 Aggregates in ALS Published in Acta Neuropathologica and Open Biology
    From ProMIS Neurosciences Inc.
    Via GlobeNewswire
    ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024
    From ProMIS Neurosciences Inc.
    Via GlobeNewswire
    ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer’s Association International Conference
    From ProMIS Neurosciences Inc.
    Via GlobeNewswire
    Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial
    From ProMIS Neurosciences Inc.
    Via GlobeNewswire
    ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing
    From ProMIS Neurosciences Inc.
    Via GlobeNewswire
    PMN Stock Earnings: ProMIS Neurosciences Beats EPS for Q1 2024
    Via InvestorPlace
    ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights
    From ProMIS Neurosciences Inc.
    Via GlobeNewswire
    ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies
    From ProMIS Neurosciences Inc.
    Via GlobeNewswire
    Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    Dow Jumps Over 300 Points; Goldman Sachs Posts Upbeat Earnings
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS
    From ProMIS Neurosciences Inc.
    Via GlobeNewswire
    ProMIS Neurosciences to Present in Upcoming Investor Conferences in April
    From ProMIS Neurosciences Inc.
    Via GlobeNewswire
    PMN Stock Earnings: ProMIS Neurosciences Beats EPS for Q4 2023
    Via InvestorPlace
    ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights
    From ProMIS Neurosciences Inc.
    Via GlobeNewswire
    ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio
    From ProMIS Neurosciences Inc.
    Via GlobeNewswire
    ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference
    From ProMIS Neurosciences Inc.
    Via GlobeNewswire
    ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine
    From ProMIS Neurosciences Inc.
    Via GlobeNewswire
    Why TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    ProMIS Neurosciences Issues Letter to Shareholders
    From ProMIS Neurosciences Inc.
    Via GlobeNewswire
    ProMIS Neurosciences, Inc. Announces Leadership Transition
    From ProMIS Neurosciences Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.